Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis

John D. Isaacs

首页> 外文期刊>Rheumatology >Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis

【24h】

Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis

机译：难治性多发性肌炎的CAMPATH-1H（alemtuzumab）后爱泼斯坦-巴尔病毒驱动的淋巴组织增生性疾病

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Rheumatology》 |2011年第4期|p.810-812|共3页
作者
John D. Isaacs;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. [J] . Cooles FA, Jackson GH, Menon G, Rheumatology . 2011,第4期

机译：难治性多发性肌炎的CAMPATH-1H（alemtuzumab）后爱泼斯坦巴尔病毒驱动的淋巴组织增生性疾病。
2. Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation [J] . Weber T., Wickenhauser C., Monecke A., Transplant infectious disease: an official journal of the Transplantation Society . 2014,第6期

机译：同种异体干细胞移植后爱泼斯坦-巴尔病毒驱动的移植后淋巴细胞增生性疾病与吞噬性淋巴细胞组织细胞增生的罕见并发治疗
3. Fulminant Epstein-Barr virus-driven CD8 positive T-cell lymphoproliferative disorder with chromosomal abnormality. [J] . Tanoshima R, Goto H, Kato H, Pediatric blood & cancer . 2011,第1期

机译：暴发性爱泼斯坦巴尔病毒驱动的CD8阳性T细胞淋巴增生性疾病，伴有染色体异常。
4. An integrated system for the monitoring of therapy and drug's side effects in Lymphoproliferative disorders [C] . Luca Vollero, Ombretta Annibali, Emiliano Schena, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2017

机译：治疗治疗和药物副作用的综合系统淋巴抑制性疾病
5. Identifying and Targeting Immune Escape Mechanisms in Epstein-Barr Virus-Driven Lymphoproliferative Disease [D] . Patton, John Thomas, Jr. 2016

机译：识别和靶向爱泼斯坦-巴尔病毒驱动的淋巴增生性疾病的免疫逃逸机制
6. Case Report: Composite Angioimmunoblastic T-Cell Lymphoma and Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder as Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders [O] . Seiji Kakiuchi, Kimikazu Yakushijin, Ikumi Takagi, 2020

机译：案例报告：复合血管免疫细胞T细胞淋巴瘤和Epstein-Barr病毒阳性B细胞淋巴抑制性疾病作为其他性能免疫缺陷相关的淋巴抑制性疾病
7. Alemtuzumab immunotherapy provides effective cytoreduction prior to allogeneic stem cell transplantation for refractory lymphoproliferative disorders [O] . Voralia M., Hasegawa W., McAllister R., 2005

机译：Alemtuzumab免疫疗法可在异基因干细胞移植之前为难治性淋巴增生性疾病提供有效的细胞减少

Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis

著录项

相似文献

相关主题

期刊订阅